Human IL-15 Antibody - Ordesekimab Biosimilar

Human IgG1 - CAS #879293-15-9 

ABOUT

Anti-human IL-15 - Ordesekimab biosimilar - CAS #879293-15-9

Anti-hIL-15-hIgG1 is a biosimilar antibody of Ordesekimab, a human interleukin-15 (IL-15) antibody that inhibits IL-15 signaling. This monoclonal antibody (mAb) is currently under investigation for the treatment of non-responsive celiac disease.

More detailsMore details

 

Anti-hIL-15-hIgG1 comprises the variable region of Ordesekimab and the IgG1 constant region of Ordesekimab.

This mAb can be used together with HEK-Blue™ IL-2/IL-15 cells for screening and neutralization assays to inhibit IL-15 signaling induced by recombinant human IL-15 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined using the EndotoxDetect™ assay.

All products are for internal research use only, and not for human or veterinary use.

Binding of anti-IL-15 mAb
Binding of anti-IL-15 mAb

SPECIFICATIONS

Specifications

Target

Human IL-15

Target species

Human

Species
Human
Isotype
hIgG1
kappa
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Ordesekimab
CAS number
879293-15-9
Synonyms
AMG 714
PRV-015
Molecular weight
145.1 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-15-hIgG1
  • Cat code: 
    hil15-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Ordesekimab and IL-15 background

Ordesekimab (also known as AMG 714 or PRV-015) is a fully human IgG1 monoclonal antibody (mAb) designed to target interleukin-15 (IL-15). By binding to IL-15, Ordesekimab inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not the interaction of IL-15 with the IL-15Rα chain [1].

IL-15 plays a vital role in supporting the function and survival of various cell types, and while its expression is normally well-controlled, elevated levels have been observed in several organ-specific autoimmune diseases [2]. In particular, it is described as a key driver of celiac disease, promoting the activation of intraepithelial CD8⁺ lymphocytes that destroy intestinal epithelial cells and lead to villous atrophy [3]. Given its central role in disease pathogenesis, IL-15 is an attractive therapeutic target. 

The anti-hIL-15 mAb Ordesekimab is currently under clinical investigation for the treatment of non-responsive celiac disease, where patients continue to experience symptoms and intestinal damage despite adherence to a gluten-free diet [1].

 

References:

1. Wei YL, et al., 2022. Strategies to evaluate potential effector function of glycan variants: a case study of ordesekimab (AMG 714 or PRV-015). J Immunotoxicol. (1):109-116.
2. Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev. 2014 Jul;260(1):221-34.
3. Lähdeaho ML, et al., 2019. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol.4(12):948-959. 

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?